This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tobey, R. A. Articles by Tesmer, J. G. Search for Related Content PubMed PubMed Citation Articles by Tobey, R. A. Articles by Tesmer, J. G.

Differential Response of Cultured Human Normal and Tumor Cells to Trace Element-induced Resistance to the Alkylating Agent Melphalan¹

Toxicology and Genetics Groups, Life Sciences Division, Los Alamos National Laboratory, University of California, Los Alamos, New Mexico 87545

Previous studies using cultured Chinese hamster cells indicated that pretreatment of the cells with the trace elements copper, selenium, and/or zinc resulted in increased survival of the metal-induced cultures following subsequent exposure to mono- and bifunctional alkylating agents. To ascertain whether a comparable protective response could be activated in humanderived material, a series of human normal and tumor cells was treated with these trace elements and later challenged with the alkylating agent melphalan, prior to determination of the surviving fraction via colony formation. Normal human cells derived from either newborn infants or adults exhibited an increase in survival of 7- to 9-fold when pretreated with zinc alone that increased to approximately 16-fold when these normal cells were induced with all three trace elements. In contrast, comparable pretreatment of tumor cell populations resulted in an increase in survival of 1.7-fold or less, with most types of tumors exhibiting no induced protection. These observations describing a differential inducibility of normal and tumor cells raise the possibility of a novel approach for selectively sparing normal tissue in patients undergoing treatment with alkylating agents. Possible ramifications to cancer chemotherapy are discussed.

¹ This research was supported by the Office of Health and Environmental Research, United States Department of Energy.

² To whom requests for reprints should be addressed, at MS M880, Los Alamos National Laboratory, Los Alamos, NM 87545.

Received 8/27/84. Revised 12/31/84. Revised 2/ 8/85. Accepted 2/12/85.

This article has been cited by other articles:

				A. K. Holzer, G. H. Manorek, and S. B. Howell Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin Mol. Pharmacol., October 1, 2006; 70(4): 1390 - 1394. [Abstract] [Full Text] [PDF]

				A. K. Holzer, N. M. Varki, Q. T. Le, M. A. Gibson, P. Naredi, and S. B. Howell Expression of the Human Copper Influx Transporter 1 in Normal and Malignant Human Tissues J. Histochem. Cytochem., September 1, 2006; 54(9): 1041 - 1049. [Abstract] [Full Text] [PDF]

				A. K. Holzer, K. Katano, L. W. J. Klomp, and S. B. Howell Cisplatin Rapidly Down-regulates Its Own Influx Transporter hCTR1 in Cultured Human Ovarian Carcinoma Cells Clin. Cancer Res., October 1, 2004; 10(19): 6744 - 6749. [Abstract] [Full Text] [PDF]

				X. Lin, T. Okuda, A. Holzer, and S. B. Howell The Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae Mol. Pharmacol., November 1, 2002; 62(5): 1154 - 1159. [Abstract] [Full Text] [PDF]